A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma.
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Oxelumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Genentech
- 18 Apr 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 18 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.